Skip to main content
RMD
NYSE Industrial Applications And Services

ResMed Q1 EPS $2.92 as MatrixCare Sale Adds $62M Gain

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$253
Mkt Cap
$35.558B
52W Low
$180.265
52W High
$277.67
52W Position info
40% above low
Off High info
8.9% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

RMD sits 40% above its 52-week low of $180.265.

Summary

ResMed reported Q1 revenue of $1.41B (+6%) and diluted EPS of $2.92, boosted by a $62M gain on the MatrixCare divestiture and a $855M quarter of share repurchases.


Key Events · Earnings and Guidance · RMD

  • Q1 Revenue Up 6% to $1.41B

    Net revenue rose to $1,414.8M from $1,335.6M, with Sleep and Breathing Health up 8% to $1,259.8M and Residential Care Software down 7% to $155.0M.

  • EPS Boosted by Divestiture Gain

    Diluted EPS was $2.92 versus $2.37; the $61.8M pre-tax gain on the MatrixCare sale contributed roughly $0.38 per share on a non-GAAP reconciliation basis.

  • MatrixCare Sale Closed September 1

    Gross proceeds were $470M with $451M net of cash divested, a $62M pre-tax gain, and $10M of divestment-related costs.

  • Heavy Buyback Shrinks Share Count

    ResMed repurchased 3.6M shares for $855M in the quarter, including a $450M ASR with an initial 1.6M shares delivered at a $230.87 reference price; 4.3M shares remain authorized.


Analysis · RMD · Industrial Applications And Services

ResMed's fiscal Q1 revenue rose 6% to $1.41B and diluted EPS jumped 23% to $2.92, but roughly $0.38 of that came from the $62M pre-tax gain on the MatrixCare sale, not operations. Core Sleep and Breathing Health revenue grew 8% while Residential Care Software fell 7% partly because MatrixCare is gone. The company also bought back 3.6M shares for $855M in the quarter, including a $450M accelerated repurchase, which shrinks the share count and flatters per-share figures. Operating income was essentially flat at $453M as R&D and SG&A both grew faster than revenue.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RMD was trading at $253.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $35.6B. The 52-week trading range was $180.27 to $277.67. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RMD - Latest Insights

RMD
Oct 29, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $252.83
Real-time Price: $239.53 info
Change: -$13.30 (-5%) info
Market Cap: $33.692B info
RMD
Sep 01, 2026, 4:39 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $231.75
Real-time Price: $239.53 info
Change: +$7.78 (+3%) info
Market Cap: $33.692B info
RMD
Sep 01, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $231.36
Real-time Price: $239.53 info
Change: +$8.17 (+4%) info
Market Cap: $33.692B info
RMD
Aug 17, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $220.37
Real-time Price: $239.53 info
Change: +$19.16 (+9%) info
Market Cap: $33.692B info
RMD
Aug 13, 2026, 5:17 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $226.74
Real-time Price: $239.53 info
Change: +$12.79 (+6%) info
Market Cap: $33.692B info